Summary

The global multiple sclerosis therapies market size reached US$ 26.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 37.8 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032.

Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple sclerosis therapies market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug, drug type, route of administration and distribution channel.
Breakup by Drug:
• Immunomodulators
o Copaxone
o Avonex/Plegridy
o Gilneya
o Tysabri
o Betaseron/Extavia
o Tecifidera
o Rebif
o Ampyra
• Immunosuppressants
o Aubagio
o Lemtrada
o Ocrelizumab
o Zinbryta

Breakup by Drug Type:
• Biologic Drugs
• Small Molecule Drugs

Breakup by Route of Administration:
• Oral
• Injectable
• Intravenous

Breakup by Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Breakup by Region:
• North America
o United States
o Canada
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Others
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Others
• Latin America
o Brazil
o Mexico
o Others
• Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:
• How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
• What are the key regional markets?
• What is the breakup of the market based on the drug?
• What is the breakup of the market based on the drug type?
• What is the breakup of the market based on the route of administration?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global multiple sclerosis therapies market and who are the key players?
• What is the degree of competition in the industry?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Multiple Sclerosis Therapies Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug
6.1 Immunomodulators
6.1.1 Market Trends
6.1.2 Major Types
6.1.2.1 Copaxone
6.1.2.2 Avonex/Plegridy
6.1.2.3 Gilneya
6.1.2.4 Tysabri
6.1.2.5 Betaseron/Extavia
6.1.2.6 Tecifidera
6.1.2.7 Rebif
6.1.2.8 Ampyra
6.1.3 Market Forecast
6.2 Immunosuppressants
6.2.1 Market Trends
6.2.2 Major Types
6.2.2.1 Aubagio
6.2.2.2 Lemtrada
6.2.2.3 Ocrelizumab
6.2.2.4 Zinbryta
6.2.3 Market Forecast
7 Market Breakup by Drug Type
7.1 Biologic Drugs
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Small Molecule Drugs
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Route of Administration
8.1 Oral
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Injectable
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Intravenous
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Online Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Abbvie Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Bayer Aktiengesellschaft
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Biogen Inc.
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Bristol-Myers Squibb Company
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 SWOT Analysis
15.3.6 GlaxoSmithKline Plc
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Merck & Co. Inc.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Novartis AG
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Sanofi S.A.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Teva Pharmaceutical Industries Ltd.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
List of Figures
Figure 1: Global: Multiple Sclerosis Therapies Market: Major Drivers and Challenges
Figure 2: Global: Multiple Sclerosis Therapies Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Multiple Sclerosis Therapies Market: Breakup by Drug (in %), 2023
Figure 4: Global: Multiple Sclerosis Therapies Market: Breakup by Drug Type (in %), 2023
Figure 5: Global: Multiple Sclerosis Therapies Market: Breakup by Route of Administration (in %), 2023
Figure 6: Global: Multiple Sclerosis Therapies Market: Breakup by Distribution Channel (in %), 2023
Figure 7: Global: Multiple Sclerosis Therapies Market: Breakup by Region (in %), 2023
Figure 8: Global: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 9: Global: Multiple Sclerosis Therapies (Immunomodulators) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Multiple Sclerosis Therapies (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Multiple Sclerosis Therapies (Oral) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Multiple Sclerosis Therapies (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Multiple Sclerosis Therapies (Injectable) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Multiple Sclerosis Therapies (Injectable) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Multiple Sclerosis Therapies (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Multiple Sclerosis Therapies (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: North America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: North America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: United States: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: United States: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: Canada: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: Canada: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: Asia Pacific: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: Asia Pacific: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: China: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 38: China: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 39: Japan: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 40: Japan: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 41: India: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 42: India: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 43: South Korea: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 44: South Korea: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 45: Australia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: Australia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: Indonesia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: Indonesia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: Europe: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: Europe: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: Germany: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: Germany: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 55: France: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 56: France: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 57: United Kingdom: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 58: United Kingdom: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 59: Italy: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 60: Italy: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 61: Spain: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 62: Spain: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 63: Russia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 64: Russia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 65: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 66: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 67: Latin America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 68: Latin America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 69: Brazil: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 70: Brazil: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 71: Mexico: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 72: Mexico: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 74: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 75: Middle East and Africa: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 76: Middle East and Africa: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 77: Global: Multiple Sclerosis Therapies Industry: SWOT Analysis
Figure 78: Global: Multiple Sclerosis Therapies Industry: Value Chain Analysis
Figure 79: Global: Multiple Sclerosis Therapies Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Multiple Sclerosis Therapies Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug (in Million US$), 2024-2032
Table 3: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
Table 4: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
Table 5: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 6: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 7: Global: Multiple Sclerosis Therapies Market Structure
Table 8: Global: Multiple Sclerosis Therapies Market: Key Player